Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,477 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Insulin-Dependent Diabetes Mellitus 1 Clear all

Conditions: Type 1 Diabetes
Interventions: Autologous UCB, Omega 3 FA, Vitamin D; Biological · Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 1 Year to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure
Interventions: Fluoxetine, Placebo control; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes
Interventions: MRI, US, and blood samples; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 8 Years to 45 Years
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Type 1 Diabetes (T1D)
Interventions: SAB-142, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 40 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more

Conditions: Type I Diabetes
Interventions: Anakinra, Placebo Comparator; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes
Interventions: MAxIM, Usual Care; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 13 Years to 17 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Hanover, New Hampshire

Conditions: Type 1 Diabetes, Obesity
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: New York, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: Artificial Pancreas Control system (APC), Pacific Diabetes Technologies CGM Insulin Infusion system; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Gastroparesis With Diabetes Mellitus
Interventions: FreeStyle Libre 3 continuous glucose monitoring sensor, Nutritional drink; Device · Other
Lead sponsor: Samita Garg; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Mellitus, Type 1
Interventions: 18F-FP-DTBZ (18F-AV-133), Arginine-hydrochloride; Drug · Biological
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hypoglycemia, Diabetes Mellitus, Type 1
Interventions: Dasiglucagon, Placebo; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Chula Vista, California • Escondido, California • Renton, Washington

Conditions: Type 1 Diabetes
Interventions: ORMD-0801 capsules- 2x8mg, ORMD-0801 capsules- 3x8mg, ORMD-0801 capsules- 1x16mg; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Selected Advanced Solid Tumors
Interventions: MEDI5752, Pemetrexed, Carboplatin, Pembrolizumab, Paclitaxel or Nab-Paclitaxel; Biological · Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Detroit, Michigan • New York, New York • Chapel Hill, North Carolina + 4 more

Conditions: Type 1 Diabetes
Interventions: Co-transplantation of PTG with pancreatic islets; Combination Product
Lead sponsor: Peter Stock; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 1 Diabetes
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 1 Diabetes
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 1 Year to 5 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 1 Diabetes Mellitus
Interventions: Liraglutide, Golimumab; Drug
Lead sponsor: Carla Greenbaum, MD; Other
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Idaho Falls, Idaho • Seattle, Washington

Conditions: Gestatiaonl Diabetes Mellitus, Pregnancy, Diabetes in Pregnancy, Insulin Dependent Diabetes Mellitus, Insulin
Interventions: Injection Port for Insulin Administration, Single-Use Insulin Needles; Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Type 1 Diabetes, Obesity, Overweight
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Bonita, California • Escondido, California • Newport Beach, California + 15 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Website; Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 1 Day to 6 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diabetes Mellitus, Type 1
Interventions: Islet Transplantation; Drug
Lead sponsor: Rodolfo Alejandro; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 1 Diabetes Mellitus
Interventions: Family Teamwork Intervention; Behavioral
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 8 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: CGM; Device
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus, Hypoglycemia, Hypoglycemia Unawareness
Interventions: Islet transplantation; Biological
Lead sponsor: Rodolfo Alejandro; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Cord Blood Plus Vitamin D and Omega 3s in T1D

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)

Pancreas Volume in Preclinical Type 1 Diabetes

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes

Incentives, Cognitive Training and Internet Therapy for Teens With Poorly Controlled Type 1 Diabetes

PET Scan Imaging of Beta Cell Mass

Single Hormone Closed Loop Study With PDT Sensor

Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes

Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes

Hypoglycemia Associated Autonomic Failure in Type 1 DM

Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes

Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

Injection Ports vs Single-Use Needles for Insulin in Pregnancy: Effects on Adherence and Satisfaction

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

A Crowdsourced Social Media Portal for Parents of Very Young Children With Type 1 Diabetes

Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

Optimizing Adherence and Glycemia in Youth With New Insulin-dependent Diabetes Mellitus (IDDM)

Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy

Allogeneic Islet Cells Transplanted Onto the Omentum